The Journal of Immunology

A new study highlights a potential therapeutic target for immune-related disorders, such as multiple sclerosis and asthma.

Tyrosine kinase inhibitors (TKI) are employed to attack specific types of cancer cells. The downside to using TKs is that they can cause serious inflammation. A team of researchers has discovered the underlying mechanism that causes this inflammation.

Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor. The finding could be utilized to control other diseases in cattle, and perhaps in humans someday.